Results 171 to 180 of about 1,668,634 (294)

Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025

Movement Disorders, EarlyView.
Abstract Background In the past decade, significant advances have improved our understanding of the mechanisms underlying HD pathobiology leading to several putative therapeutic targets for HD. Objective The aim was to describe the Huntington's disease (HD) drug development clinical pipeline.
Pavlina Konstantinova, Jenny Townhill, Juliana Bronzova, Viktoria Andreeva, Swati Sathe, Cristina Sampaio   +5 more
wiley   +1 more source

Comorbid mechanisms of psoriasis and mental disorders: an analysis of inflammatory and psychosocial interactions. [PDF]

Front Psychiatry
Qin B, Pang H, Huang Y, Chen C, Yang Y, Tian Y, Zhang Y.   +6 more
europepmc   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source

Chemotherapy-Induced Brain Damage: Mechanisms and Insights from Rodent Models. [PDF]

Brain Sci
Veljković M, Džopalić T, Ranđelović P, Popović Dragonjić L, Milenković J, Ilić I.   +5 more
europepmc   +1 more source

“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan, Alyssa Kobayashi, Zhina Sadeghi   +2 more
wiley   +1 more source

Aberrant Functional Lateralization and Interhemispheric Synergy in High Myopia: Insights From Neurotransmitter Distribution Signatures and Machine Learning Classification. [PDF]

Invest Ophthalmol Vis Sci
Zhou L, Wang Y, Xiong S, Ji Y, Dong ZE, Zeng X, Wu XR.   +6 more
europepmc   +1 more source

Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation

Neuroprotection, EarlyView.
Abstract Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template.
Tianshan Ji, Yuan Zhang, Jinyi Zhao, Yiping Lu, Chengkun Wang   +4 more
wiley   +1 more source

Parkinson's disease drug therapies in the clinical trial pipeline: 2015-2024. [PDF]

J Parkinsons Dis
Buff S, Pilcicka A, Pitzer K, Fiske B, Stott SR, McFarthing K.   +5 more
europepmc   +1 more source

Repurposing antimicrobial agents for neuroprotection: Mechanisms, clinical potential, and challenges

Neuroprotection, EarlyView.
Antimicrobial agents exert neuroprotective effects through modulation of interconnected pathways. Tetracyclines, macrolides, antimalarial agents, sulfones, and antiparasitic agents suppress neuroinflammation, oxidative stress, and apoptosis while preserving mitochondrial function and neurotransmission.
Mohammad Amin Manavi, Mohammadreza Salehi, Razieh Mohammad Jafari, Ramin Goudarzi, Saman Khosravi, Ahmad Reza Dehpour   +5 more
wiley   +1 more source

Herbal Neurotherapeutics for Cognitive Disorders: Integrative Mechanisms Linking Neurotransmitter Systems, Neurodegeneration, and the Gut-Brain Axis. [PDF]

Nutrients
Rahman M, Akter K, Rani A, Park MN, Kim B.   +4 more
europepmc   +1 more source